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ABSTRACT 
 
There are over two hundred million cases of malaria each year.  Although there are 
effective treatments, drug resistant strains are emerging that make discovery of new antimalarials 
an important goal. We have developed a semi-automated assay platform to screen novel 
compounds for their ability to kill Plasmodium falciparum, the parasite that causes the most 
deadly form of human malaria.  This assay was used to screen novel analogs of curcumin, a 
component of the spice turmeric, which is known to have antimalarial activity.  Several of these 
analogs were found to inhibit parasite growth at low-micromolar to sub-micromolar 
concentrations.  The compounds in this collection represent eight structural classes, and a 
structure-activity relationship analysis indicates a class-specific potency.  Monocarbonyls had 
relatively high potency, while coumarins had very little activity against the parasite.  The 
heteroaromatic and aromatic class of compounds are the most promising for future study because 
compounds in this class had very little activity against mammalian cell lines, indicating high 
selectivity for the parasite.  Curcumin inhibits parasite growth at an IC50 of 6.06 µM while the 
most promising and selective compound in this screen, compound 47, is an aromatic compound 
with an IC50 of 0.512µM.  We have developed an assay to investigate interactions between these 
compounds and current antimalarials in combination, and we hope to determine whether the 
promising compounds may be used effectively in combination with other existing antimalarials. 
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CHAPTER 1 
INTRODUCTION 
 Malaria is a devastating disease in many developing countries that infects over two 
hundred million people per year, killing an estimated 655,000 people in 2010 (1). It is the second 
leading cause of death from infectious disease in Africa, where 89% of worldwide malaria deaths 
occur (Figure 1) (2).  
Figure 1. Geographical distribution of malaria transmission (2). 
Plasmodium falciparum is the protozoan parasite that causes the most deadly form of 
human malaria.  It is transmitted by the female Anopheles mosquito.  Parasites are passed into 
the human blood stream by the mosquito, where they first replicate in hepatocytes.  The parasite 
then goes through asexual replication cycles in the erythrocytes.  The parasites mature from ring 
state to trophozoites to schizonts, and mature schizonts rupture the erythrocyte, releasing 
merozoites that infect new erythrocytes.  Parasites can also differentiate into gametocytes, which 
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are ingested by the Anopheles mosquito during a blood meal.  The blood stages of the parasite 
life cycle are responsible for the symptomatic stages of malaria (Figure 2). 
Figure 2. Life cycle of Plasmodium falciparum (2).  The sporogonic cycle occurs in the 
Anopheles mosquito, the exo-erythrocytic cycle occurs in the human liver, and the erythrocytic 
cycle is the diagnostic stage, which is responsible for the symptoms of malaria. 
 
 The symptoms of uncomplicated malaria include fever, chills, headache, sweats, body 
aches, nausea, and malaise.  The classical malaria attack consists of three stages: a cold stage 
with chills and shivering, a hot stage with fever, vomiting, and sometimes seizures, and a 
sweating stage characterized by sweating, returning to normal temperature, and tiredness.  The 
whole attack typically lasts 6-10 hours.  Severe malaria is much more serious and can include 
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cerebral malaria, anemia, acute respiratory distress syndrome, low blood pressure, and kidney 
failure (2).   
Although effective drugs are available for malaria, the emergence of drug resistance 
makes treatment a challenge and necessitates the development of new antimalarials.  Resistance, 
increased tolerance, or treatment failure has been documented for every antimalarial on the 
market, including recent reports of resistance to artemisinin in Cambodia and Thailand (3).  
Artemisinin combination therapy is currently the first-line treatment recommended by the World 
Health Organization (WHO).  Given this developing resistance to even the most effective and 
widely used antimalarials, drug discovery has an important role in combating malaria. 
Figure 3. Plasmodium falciparum drug resistance (4).  Chloroquine, sulfadoxine-
pyrimethamine, and mefloquine resistance is widespread in malaria-endemic areas. 
 
 Curcumin is the component of the spice turmeric that gives it its yellow color.  It is 
obtained from the root of the plant Curcuma longa, and has been used in traditional medicine for 
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many purposes including liver disease, arthritis, and insect bites.  It has been shown to have 
activity against both chloroquine (CQ) sensitive and chloroquine resistant parasites (5).  In 
addition to its antimalarial properties, curcumin has been shown to suppress growth of pancreatic 
and breast cancer cells (6).  The Fuchs lab in The Ohio State University College of Pharmacy has 
created a library of curcumin analogs.  Given the known antimalarial properties of curcumin, we 
screened this library in order to determine of any of the analogs are more potent than curcumin 
itself. 
CHAPTER 2 
MATERIALS AND METHODS 
Parasite culture 
Asynchronous 3D7 MR4 parasites were co-cultured with human O-positive erythrocytes 
(Interstate Blood Bank) in 12 mL volumes at 2% hematocrit.  The media was RPMI 1640 with 
0.5% Albumax (Gibco), 11.1mM glucose, 26.8mM NaHCO3, 50µg/mL hypoxanthene, and 
10µg/mL gentamicin (Sigma).  The cultures were incubated at 37ºC in 5% O2, 5% CO2, and 90% 
N2. 
IC50 Assay 
The IC50 assays were performed in a 384-well plate using optimized conditions for 
parasite growth in small volumes (75µL/well, 1% hematocrit, 1-1.5% initial parasitemia).  
37.5µL of RPMI was added to the plate, and the drugs were serially diluted using 2.5-fold 
dilution with a Biomek 2000 to give a concentration range of 80µM to 0.131µM.  37.5µL of 
asynchronous culture (2% hematocrit, 1-1.5% parasitemia) was added to each well to give a final 
hematocrit of 1%, drug concentrations of 40µM to 0.065µM, 1-1.5% parasitemia, and maximum 
0.4% DMSO.  The cultures were incubated at 37ºC in 5% O2, 5% CO2, and 90% N2.  After 72 
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hours the cultures were resuspended and a 2.5µL sample was added to 50µL of 1.5µg/mL 
acridine orange in PBS and shaken for 30 seconds at 1500rpm.  The parasitemia was determined 
using high-throughput flow cytometry with a BD FACS Canto II.  IC50s were calculated using 
the sigmoidal dose-response variable slope equation in GraphPad PRISM. 
Isobologram 
The isobologram assay was based on the fixed-ratio isobologram described in Fivelman 
et al (7) and was modified to be performed in 384-well plate format using the Biomek.  IC50 
assays were first dome to determine the IC50 of each drug. The two drugs were combined for the 
isobologram assay so that the IC50 fell at about the sixth twofold serial dilution.  The 
combination solutions were prepared with fixed ratios (Figure 6A) so that the highest 
concentration of each drug was 0.50 µM (combination 1 for artemisinin, combination 10 for 
CQ). The combinations were placed in triplicate in columns 1 and 13 of a 384-well plate, with 
row P as a no drug control.  Each combination was serially diluted into RPMI by the Biomek in a 
twofold serial dilution across a 1000-fold range, and culture was added using the conditions 
optimized for parasite growth in small volumes.  The plate was incubated at 37ºC in 5% O2, 5% 
CO2, and 90% N2.  After 72 hours parasitemia was determined using flow cytometry as 
described above, and two fractional inhibitory concentrations were calculated for each 
combination using the concentration of a single drug.  The fractional inhibitory concentration 
was calculated as IC50 of drug in combination divided by IC50 of drug alone.  The isobologram 
was plotted with each drug’s FIC50 on an axis, where points above the control line represent 
antagonism and points below the control line represent synergy. 
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CHAPTER 3 
RESULTS 
Assay Development 
 In order to screen compounds for their effectiveness at inhibiting P. falciparum growth, 
we developed a semi-automated assay.  The assay is used to screen either ten or fifteen 
compounds at a time in a 384-well plate format.  Optimal conditions for culture growth in small 
volumes were determined in order to provide the best environment for parasite growth for the 
assay.  The four variables to be optimized for the assay are culture volume, initial parasitemia, 
incubation time, and hematocrit.   
 
 
Figure 4. Optimization of Plasmodium falciparum growth assay conditions.  (A) Culture growth 
with varied hematocrit.  (B) Culture growth with varied volume (µL). 
 
 The optimal hematocrit (percent red blood cells by volume) for growth in small volumes 
was found to be 1%.  Similar growth was observed in wells containing 50µL, 75µL, and 100µL 
of culture.  75µL per well was chosen for the assay due to concerns about evaporative loss over 
the incubation period with small volumes.  The cycle time for 3D7 MR4 parasites is 34 hours, so 
an incubation length of 72 hours was chosen in order to make sure that all parasites went through 
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at least one full cycle.  A 48-hour assay would also allow for at least one erythrocytic cycle, but 
72 hours also allows for IC50 determination for drugs that display a delayed death phenotype.  
The initial parasitemia (percent parasitized red blood cells) was set at 1-1.5% for the assay in 
order to allow the parasites to grow to a point where a noticeable difference in parasitemia could 
be observed between treated and untreated cultures.  Untreated cultures starting at 1-1.5% can 
grow to about 20% parasitemia over a 72-hour period.  The compounds were dispensed over a 
range of concentrations using a Biomek 2000 liquid-handling robot and culture was added 
according to the optimized conditions.  After incubation, parasitemia was determined by flow 
cytometry and dose-response curves were generated using GraphPad Prism software. 
Screening and Structure-Activity Relationship Analysis 
The Fuchs lab in The Ohio State University College of Pharmacy created a library of 109 
novel curcumin analogs, which were screened against P. falciparum using the high-throughput 
approach described above to determine the IC50, the concentration of drug that inhibits parasite 
growth by 50%.  The semi-automated assay was used to generate dose-response curves and 
determine IC50s for all 109 compounds.  The Fuchs lab also divided the compounds into eight 
structural classes so that relationships between structure and activity could be more effectively 
studied (Table 1).   
Class Structure 
Curcumin-like 
  
Dialkylated Curcumin 
  
 13 
Monocarbonyls 
  
Imides 
  
Heteroaromatic/aromatic 
  
Coumarins 
  
Amides 
  
Miscellaneous 
  
 
Table 1.  Representative structures for each class of curcumin analogs. 
 
A structure-activity relationship (SAR) analysis shows that the dialkylated curcumin 
compounds and the monocarbonyls are very potent; many of the compounds in these categories 
had IC50s lower than that of curcumin.  The imides and coumarins show very little potency; 
almost all of these compounds had IC50s that were greater than 40µM.  The 
heteroaromatic/aromatic class was mostly not active, with the exception of compounds 30 and 
47.  There is some variation in the amides and curcumin-like compounds, but in general they are 
not very potent (Figure 5). 
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Figure 5. Differences in potency are dependent on the class of analogs. 
 Although all of the analogs are structurally based on curcumin, they have very different 
structures and widely varying IC50s.  The ten most potent compounds from the first screen were 
screened again to verify their potency.  The two most potent, compounds 64 and 47, have similar 
IC50s but come from different classes and have markedly different structures.  Artemisinin, the 
current first-line treatment for malaria, has an IC50 of 0.010 µM.  The lowest IC50 in this screen 
was compound 64, which has an IC50 of 0.488 µM (Table 2).  Several compounds in the screen 
had IC50s over 40 µM, while curcumin (compound 1) has an IC50 of 6.06 µM. 
Compound IC50 (µM) Class Structure 
64 0.488  ± 0.32 Monocarbonyls 
 
47 0.512 ± 0.086 Heteroaromatic/aromatic 
 
Po
te
nc
y 
(1
/IC
50
, µ
M
) 
Curcumin-like Dialkylated  
curcumin 
Monocarbonyls Misc. Imides Heteroaromatic/ 
aromatic 
Coumarins Amides 
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55 0.708 ± 0.41 Dialkylated curcumin 
 
54 1.011 ± 0.41 Dialkylated curcumin 
 
12 1.249  ± 0.88 Monocarbonyls 
 
36 1.287  ± 0.72 Dialkylated curcumin 
 
13 1.329 ± 1.2 Monocarbonyls 
 
32 1.352  ± 0.69 Monocarbonyls 
 
25 1.682  ± 1.5 Monocarbonyls 
 
30 1.824  ± 1.9 Heteroaromatic/aromatic 
 
Table 2.  Top ten curcumin analogs and their IC50s.  The top ten compounds come from three 
different classes and have IC50s below 2 µM.  The IC50s are the average of two different assays. 
 
The top ten compounds come from three different categories, and have IC50s in the low-
micromolar to sub-micromolar range.  The only categories with compounds in the top ten are 
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monocarbonyls, heteroaromatic/aromatic and dialkylated curcumin.  In order to further prioritize 
compounds for their potential as an antimalarial the compounds’ IC50s against mammalian cell 
lines were compared.  A good antimalarial should be selective for the parasite, meaning that it is 
toxic to the parasite and not to human cells.  The comparison of IC50s between mammalian cells 
and parasite cultures allows us to compare toxicity and identify compounds that are selective for 
the parasite.   The heteroaromatic/aromatic class of compounds had low IC50s against P. 
falciparum and high IC50s against two mammalian cell lines, a prostate cancer cell line and a 
breast cancer cell line.  The imide class of analogs, on the other hand, had very high IC50s against 
Plasmodium falciparum and low IC50s against the mammalian cell lines (Table 3). 
Compound Class Plasmodium 
(IC50 µM) 
DU-145 
(IC50 µM) 
MDA-MB-
231 (IC50 µM) 
30 Heteroaromatic/aromatic 1.824  ± 1.9 16.1 ± 3.4 > 50 
47 Heteroaromatic/aromatic 0.512  ± 0.086 >50 > 50 
55 Dialkylated curcumin 0.708  ± 0.41 1.3 ± 0.2 1.9 ± 0.5 
54 Dialkylated curcumin 1.011  ± 0.41 2.7 ± 1.2 -1.7 ± 0.5 
36 Dialkylated curcumin 1.287  ± 0.72 4.7 ± 0.03 -6.5 ± 0.5 
64 Monocarbonyls 0.488  ± 0.32 -0.5 ± 0.06 -1.6 ± 0.7 
98 Imides >40 2.3 ± 0.1 -1.7 ± 0.5 
109 Imides ~16.60 4.1 ± 0.9 -1.6 ± 0.4 
 
Table 3.  A comparison of IC50s for several compounds against Plasmodium falciparum and 
mammalian cell lines. The DU-145 (a prostate cancer cell line) and MDA-MB-231 (a breast 
cancer cell line) data came from the Fuchs lab in the OSU College of Pharmacy. 
 
 Since the parasite circulates in the bloodstream in infected individuals, it is also important 
to determine the toxicity of the drugs against erythrocytes.   Four compounds were incubated 
with unparasitized erythrocytes at the IC90 concentration to determine if there was a significant 
change in hematocrit due to the effects of the drug (Table 4).  The high concentration of the drug 
should allow for any toxicity to be apparent when the red blood cells are exposed to the drug for 
72 hours.  Although the hematocrit decreased over the course of 72 hours, the difference in 
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hematocrit is due to the natural breakdown of erythrocytes over time and not due to exposure to 
the drug. 
Compound IC90 (µM) Initial hematocrit 72 hr. hematocrit 
Curcumin 11.61 
4.17% 
3.51% 
30 3.42 3.09% 
64 1.13 3.86% 
No drug 0 3.19% 
  
Table 4.  Hemolysis assay for selected compounds at the IC90.  Unparasitized red blood cells 
were incubated with a high concentration of drug, showing no difference in hemolysis between 
the treated and untreated erythrocytes. 
 
Isobolograms 
In order to study the interactions between two drugs, an assay called an isobologram is 
used.  Additive effects have been reported between the current first-line antimalarial, artemisinin, 
and curcumin (8).  The semi-automated assay for determining drug interactions was created 
based on the protocol described in Fivelman, et al (7).  The isobologram is performed by 
combining two drugs in varying ratios (Figure 6A).  Each combination is then serially diluted by 
the Biomek robot so that the IC50 values fall in the middle of the dilution.  The combinations are 
incubated with parasite culture and inhibition is calculated in a manner similar to an IC50 assay 
for each drug individually, taking into account only the concentration of that drug in the 
combination (Figure 6B).  The fractional IC50 (FIC50) for each drug combination is calculated as 
the IC50 for that drug in the combination divided by the IC50 of the drug alone.  The fractional 
IC50s for each drug combination are plotted against each other, and the fractional IC50 represents 
the contribution to the total inhibition from the individual drug.  A line is drawn on the graph 
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connecting a FIC50 of 1 for each drug. If the points are below 1 on the graph they represent 
synergy because there is more inhibition from the combination than can be accounted for by the 
two drugs individual effects.  Points on the line indicate an additive effect, and points above the 
line indicate an antagonistic effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Fixed-ratio isobologram.  (A) Ratio of drugs in each solution. (B) Fractional IC50s for 
artemisinin and CQ.  (C) Isobologram showing antagonism between artemisinin and CQ. 
 
Combination 
Solution 
Ratio of Artemisinin to CQ 
Artemisinin CQ 
1 9 0 
2 8 1 
3 7 2 
4 6 3 
5 5 4 
6 4 5 
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8 2 7 
9 1 8 
10 0 9 
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 The points lie mainly above the line, indicating an antagonistic relationship between 
chloroquine (CQ) and artemisinin (Figure 6C).  We have successfully used the semi-automated 
isobologram assay to demonstrate the expected antagonistic effects between artemisinin and 
chloroquine (9).  This assay will soon be used to determine the interactions between promising 
curcumin analogs and artemisinin. 
CHAPTER 4 
DISCUSSION 
 We have carried out a multiple-step screening approach to determine which of the 
curcumin analogs in this library are promising drugs for future study.  Initially, all 109 
compounds were screened using a semi-automated assay where a Biomek 2000 liquid-handling 
robot dispenses compounds and culture.  This allows for the assay to be carried out in a 384-well 
plate format.  Dose-response curves were generated and IC50 values calculated for all of the 
compounds.  Curcumin (compound 1) has an IC50 of 6.06 µM, and there were several 
compounds that had IC50s lower than that of curcumin.  The ten most potent compounds from the 
initial screen were screened again, and these ten compounds were considered the most promising 
for future study.   
 The Fuchs lab in the OSU College of Pharmacy divided the library into eight structural 
classes, with widely varying potencies.  The monocarbonyls and dialkylated curcumin analogs 
were relatively potent, while the imides and coumarins had very little potency.  The curcumin-
like, amides, and miscellaneous compounds had intermediate potency.  Interestingly, most of the 
compounds in the heteroaromatic/aromatic class had low to intermediate potency, with the 
exception of compounds 30 and 47.  The compounds have similar structures, but compound 47 is 
an aromatic compound and compound 30 is a heteroaromatic compound.  The structural feature 
 20 
that makes these two compounds so much more potent than other heteroaromatic/aromatic 
compounds is unknown. 
 In order to determine which classes of compounds are most selective for the parasite, the 
IC50 against Plasmodium falciparum was compared to previously obtained data from the Fuchs 
lab on the IC50s against two mammalian cell lines.  Both potent aromatic/heteroaromatic 
compounds, 30 and 47, had very low IC50s against Plasmodium and high IC50s against the 
mammalian cells.  The heteroaromatic/aromatic compounds selectively inhibit growth of the 
parasite, making them even more promising class of analogs.  In contrast, the imides had high 
IC50s against the parasite and low IC50s against the mammalian cell lines.  The monocarbonyls 
and dialkylated curcumin analogs had similar potency for all cell lines, indicating that they have 
a broad cytotoxic effect and are not specific.  The effect of the drug on the erythrocyte was also 
considered.  When nonparasitized red blood cells were incubated at the IC90 for 72 hours, there 
was no significant hemolytic effect from the drug as compared to a no-drug control.   
 In order to delay the emergence of drug resistance, combination therapies for malaria are 
preferred over monotherapies.  The currently recommended combination therapy is artemisinin-
based.  Since additive effects have been reported between curcumin and artemisinin (8), 
determining the interactions between the promising compounds from this screen is important in 
further investigating the heteroaromatic/aromatic compounds.  The isobologram assay for 
determining synergy, antagonism, or additive effects has been developed using the Biomek 
robot, and can soon be used for the curcumin analogs.  The interactions between artemisinin and 
compounds 47 and 30 are of particular interest since they are the most promising of the curcumin 
analogs. 
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 This screen has identified several compounds that inhibit parasite growth at low-
micromolar or sub-micromolar concentrations, all of which have a lower IC50 than the parent 
compound, curcumin.  One class of analogs in particular, heteroaromatic/aromatic compounds, 
included two drugs which were selective inhibitors of parasite growth with no adverse effects on 
mammalian cells.  This promising class of compounds should be further investigated, especially 
to determine the mechanism of action and their effects on resistant parasites. 
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APPENDICES 
Appendix A 
Structures of all analogs 
Curcumin-like:  8 compounds 
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Heteroaromatic/aromatic:  13 compounds 
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Monocarbonyls:  29 compounds 
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Amides:  26 compounds 
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Coumarins:  4 compounds 
 
 
Imides:  8 compounds 
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Miscellaneous:  3 compounds 
 
 
Note: compound 59 was a duplicate of one of the other compounds in the library and was 
removed. 
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Appendix B 
IC50s of all analogs 
Compound IC50 (µM) 
Curcumin-like 
1 6.06 ±0.36 
2 10.5 
6 ~2.60 
16 >40 
17 2.66 
18 3.00 
20 ~6.74 
23 >40 
Dialkylated Curcumin 
3 1.84 
33 1.30 
36 1.287  ± 0.72 
37 2.41 
38 1.17 
39 3.88 
40 1.53 
41 2.16 
42 3.59 
43 1.20 
 31 
50 1.10 
51 2.57 
53 2.07 
54 1.011 ± 0.41 
55 0.708 ± 0.41 
56 8.55 
57 1.81 
58 3.93 
Heteroaromatic/aromatic 
4 17.9 
5 3.64 
29 19.1 
30 1.824  ± 1.9 
31 >40 
34 4.45 
35 11.0 
47 0.512 ± 0.086 
48 7.03 
60 4.45 
61 5.20 
81 5.08 
82 5.03 
Monocarbonyls 
 32 
7 4.62 
8 7.67 
9 2.90 
10 4.10 
11 2.70 
12 1.249  ± 0.88 
13 1.329 ± 1.2 
14 9.73 
15 16.7 
19 >40 
21 >40 
22 1.11 
24 13.8 
25 1.682  ± 1.5 
28 ~18.3 
32 1.352  ± 0.69 
49 1.56 
52 1.87 
62 12.9 
63 1.67 
64 0.488  ± 0.32 
66 >40 
67 4.32 
 33 
68 1.14 
69 >40 
70 6.73 
71 >40 
79 2.91 
83 9.72 
Amides 
26 >40 
27 12.0 
65 >40 
72 >40 
73 14.6 
74 7.27 
75 >40 
76 7.99 
77 13.6 
78 >40 
80 >40 
84 1.42 
85 2.49 
86 7.51 
87 10.1 
88 >40 
 34 
89 >40 
90 2.91 
91 3.61 
92 11.9 
93 12.9 
94 8.51 
95 29.6 
96 12.9 
97 >40 
99 >40 
Coumarins 
104 >40 
105 >40 
105 >40 
110 >40 
Imides 
98 >40 
100 32.2 
101 >40 
102 >40 
103 >40 
107 >40 
108 >40 
 35 
109 ~16.6 
Miscellaneous 
44 8.70 
45 4.14 
46 3.96 
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